[go: up one dir, main page]

NO20051107L - Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet - Google Patents

Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet

Info

Publication number
NO20051107L
NO20051107L NO20051107A NO20051107A NO20051107L NO 20051107 L NO20051107 L NO 20051107L NO 20051107 A NO20051107 A NO 20051107A NO 20051107 A NO20051107 A NO 20051107A NO 20051107 L NO20051107 L NO 20051107L
Authority
NO
Norway
Prior art keywords
treatment
deacetylea
activity
diseases associated
hydroxamic acids
Prior art date
Application number
NO20051107A
Other languages
English (en)
Norwegian (no)
Inventor
Neil Victor Harris
Janet Ann Archer
Walter Bordogna
Richard James Bull
David Edward Clark
Hazel Joan Dyke
Matthew Iain Andrew Gill
Marco Van Den Heuvel
Stephen Price
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218040A external-priority patent/GB0218040D0/en
Priority claimed from GB0310462A external-priority patent/GB0310462D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of NO20051107L publication Critical patent/NO20051107L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
NO20051107A 2002-08-02 2005-03-01 Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet NO20051107L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218040A GB0218040D0 (en) 2002-08-02 2002-08-02 Chemical compounds
GB0310462A GB0310462D0 (en) 2003-05-07 2003-05-07 Chemical compounds
PCT/GB2003/003168 WO2004013130A1 (fr) 2002-08-02 2003-07-24 Acides substitues thienylhydroxamiques utilises en tant qu'inhibiteurs d'histone desacetylase

Publications (1)

Publication Number Publication Date
NO20051107L true NO20051107L (no) 2005-04-20

Family

ID=31497256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051107A NO20051107L (no) 2002-08-02 2005-03-01 Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet

Country Status (18)

Country Link
US (1) US20060122234A1 (fr)
EP (1) EP1525199A1 (fr)
JP (1) JP2005539001A (fr)
KR (1) KR20050034732A (fr)
CN (1) CN1684957A (fr)
AR (1) AR040765A1 (fr)
AU (1) AU2003255724A1 (fr)
BR (1) BR0313371A (fr)
CA (1) CA2494114A1 (fr)
EC (1) ECSP055636A (fr)
IL (1) IL166603A0 (fr)
MX (1) MXPA05001334A (fr)
NO (1) NO20051107L (fr)
PE (1) PE20050121A1 (fr)
PL (1) PL374970A1 (fr)
RU (1) RU2005105696A (fr)
UY (1) UY27921A1 (fr)
WO (1) WO2004013130A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040804A2 (en) 2002-03-13 2005-02-28 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
WO2003076400A1 (fr) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Nouveaux inhibiteurs de l'histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
CN100503599C (zh) 2002-03-13 2009-06-24 詹森药业有限公司 作为组蛋白脱乙酰酶的新颖抑制剂的羰基氨基衍生物
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
AU2003236500B9 (en) * 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN102304110A (zh) 2003-04-07 2012-01-04 Axys药物公司 作为治疗剂的异羟肟酸酯
WO2005014588A1 (fr) * 2003-08-01 2005-02-17 Argenta Discovery Limited Acides hydroxamiques de thienyle substitues presentant une activite de deacetylase
US7935724B2 (en) * 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
EP1682538A4 (fr) * 2003-10-27 2009-05-27 S Bio Pte Ltd Hydroxamates lies au biaryle: preparation et applications pharmaceutiques
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
UA86066C2 (ru) 2004-07-28 2009-03-25 Янссен Фармацевтика Н.В. Производные замещенного пропенилпиперазина как ингибиторы гистондеацетилазы
ITMI20060621A1 (it) * 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
WO2006066133A2 (fr) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
US20080213399A1 (en) 2005-02-03 2008-09-04 Topotarget Uk Limited Combination Therapies Using Hdac Inhibitors
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
EP1863756A1 (fr) * 2005-03-24 2007-12-12 Janssen Pharmaceutica N.V. Amides derives de biaryle modulateurs de recepteur vanilloide vr1
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1901729B1 (fr) 2005-05-13 2012-01-25 TopoTarget UK Limited Formulations pharmaceutiques d'inhibiteurs de hdac
EP1885710B1 (fr) 2005-05-18 2015-08-19 Janssen Pharmaceutica N.V. Dérivés substitués d'aminopropenyl-piperidine ou de morpholine utilisés en tant qu'inhibiteurs de l'histone-désacétylase
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1943232B1 (fr) 2005-10-27 2011-05-18 Janssen Pharmaceutica NV Dérivés d'acide squarique en tant qu'inhibiteurs d'histone désacétylase
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
EP1979328B1 (fr) 2006-01-19 2012-12-26 Janssen Pharmaceutica N.V. Dérivés de pyridine et de pyrimidine en tant qu'inibiteurs d'histone désacétylase
CA2635015C (fr) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Derive d'indolyl-alkyl-amino substitues en tant qu'inhibiteurs d'histone desacetylase
PT1981874E (pt) 2006-01-19 2009-09-02 Janssen Pharmactuica N V Derivados de aminofenil como novos inibidores de histonadesacetilase
US8101616B2 (en) 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
ES2396986T3 (es) 2006-01-19 2013-03-01 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
WO2007100851A1 (fr) * 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Composes therapeutiques
NZ570844A (en) 2006-02-28 2011-11-25 Helicon Therapeutics Inc Therapeutic piperazines as PDE4 inhibitors
GB0613518D0 (en) * 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
EP1878730A1 (fr) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Isoxazolines substituées, compositions pharmaceutiques les comprenant, procédés pour leur préparation et leur usage
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
MX2009004279A (es) 2006-10-30 2009-05-22 Chroma Therapeutics Ltd Hidroxamatos como inhibidores de histona desacetilasa.
WO2008062878A1 (fr) * 2006-11-22 2008-05-29 Nihon Nohyaku Co., Ltd. Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles
CA2672776A1 (fr) * 2006-12-20 2008-06-26 Novartis Ag Composes organiques
SI2099442T1 (sl) 2006-12-26 2015-03-31 Pharmacyclics, Inc. Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
US7838234B2 (en) 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008101186A1 (fr) * 2007-02-15 2008-08-21 The J. David Gladstone Institutes Inhibiteurs de hdac8
WO2008117861A1 (fr) * 2007-03-28 2008-10-02 Santen Pharmaceutical Co., Ltd. Agents diminuant la pression intraoculaire contenant des dérivés de phénylènediamine en tant que principe actif
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
CN101868446A (zh) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
CA2702126A1 (fr) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t a base d'amide heterocyclique
EP2217588A4 (fr) * 2007-11-02 2013-12-04 Methylgene Inc Inhibiteurs de l'histone déacétylase
WO2009079375A1 (fr) * 2007-12-14 2009-06-25 Georgetown University Inhibiteurs de l'histone déacétylase
ES2395347T3 (es) 2008-03-27 2013-02-12 Janssen Pharmaceutica, N.V. Derivados de indolilalquilamino sustituidos con aza-biciclohexilo como inhibidores novedosos de histona desacetilasa
WO2009137081A2 (fr) * 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Inhibiteurs à petites molécules de dihydroorotate déshydrogénase de plasmodium falciparum
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2011089995A1 (fr) * 2010-01-21 2011-07-28 公立大学法人名古屋市立大学 Dérivé de l'acide hydroxamique et inhibiteur de hdac8 l'utilisant
ES2603032T3 (es) 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
EP2630133A1 (fr) 2010-10-22 2013-08-28 Bayer Intellectual Property GmbH Nouveaux composés hétérocycliques utilisés en tant qu'agents pour lutter contre des nuisibles
WO2012112447A2 (fr) * 2011-02-14 2012-08-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de l'histone déacétylase et leurs méthodes d'utilisation
SG2014014419A (en) 2011-09-13 2014-07-30 Pharmacyclics Inc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
JPWO2013141362A1 (ja) * 2012-03-23 2015-08-03 日本農薬株式会社 チアゾールカルボキサミド誘導体及びその使用方法
JP6183053B2 (ja) * 2012-08-22 2017-08-23 宇部興産株式会社 テトラヒドロピラニルピリミジン化合物の製造方法
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
EP3769757A3 (fr) * 2013-10-18 2021-10-06 The General Hospital Corporation Imagerie d'histone désacétylases au moyen d'un radiotraceur à l'aide de la tomographie par émission de positrons
WO2015172196A1 (fr) * 2014-05-13 2015-11-19 Monash University Composés hétérocycliques et leur utilisation
CN108379585B (zh) * 2018-04-16 2020-10-16 复旦大学附属中山医院 Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
CN111072582B (zh) * 2018-10-18 2024-06-18 中国药科大学 一种n－羟基芳杂环－2－甲酰胺化合物及其制备方法和用途
CN111100071A (zh) * 2019-12-19 2020-05-05 西安近代化学研究所 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法
CN119143740B (zh) * 2024-08-15 2025-11-14 杭州科兴生物化工有限公司 一种苯并噻吩类衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
EP2083005A1 (fr) * 2000-09-29 2009-07-29 TopoTarget UK Limited Composés d'acide carbamique comportant une liaison d'amide en tant qu'inhibiteurs HDAC

Also Published As

Publication number Publication date
CA2494114A1 (fr) 2004-02-12
BR0313371A (pt) 2005-07-05
WO2004013130A1 (fr) 2004-02-12
IL166603A0 (en) 2006-01-15
CN1684957A (zh) 2005-10-19
EP1525199A1 (fr) 2005-04-27
UY27921A1 (es) 2004-02-27
US20060122234A1 (en) 2006-06-08
PL374970A1 (en) 2005-11-14
KR20050034732A (ko) 2005-04-14
AR040765A1 (es) 2005-04-20
MXPA05001334A (es) 2005-09-08
AU2003255724A1 (en) 2004-02-23
RU2005105696A (ru) 2005-11-10
ECSP055636A (es) 2005-05-30
JP2005539001A (ja) 2005-12-22
PE20050121A1 (es) 2005-03-12

Similar Documents

Publication Publication Date Title
NO20051107L (no) Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
DE602004004665D1 (en) Acetylenderivate als inhibitoren von histondeacetylase
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
DK1590340T3 (da) Histondeacetylase-inhibitorer
NO20002440D0 (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
WO2003066579A3 (fr) Nouveaux hydroxamates bicycliques servant d'inhibiteurs de histone desacetylase
EA200501700A1 (ru) Применение эффектов глутаминил- и глутаматциклаз
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
DK1701946T3 (da) 1-piperazin- og 1-homopiperazincarboxylatderivater, deres fremstilling og deres terapeutiske anvendelse som inhibitorer af FAAH-enzymet
PT1208086E (pt) Formulacao de benzamida com actividade inibiodora de histona desacetilase.
EP2620150A3 (fr) Inhibiteurs à base de 2-amido thiazole d'enzymes utilisant l'ATP
WO2002007722A3 (fr) Acide valproique et derives de ce dernier utiles en tant qu'inhibiteurs de l'histone deacetylase
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20051788L (no) Hydantoinderivater og deres anvendelse som TACE-inhibitorer
TW200714600A (en) Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
WO2004043352A3 (fr) Inhibiteurs de l'histone desacetylase pour le traitement de maladies et de troubles oculaires, neovasculaires ou oedemateux
NO20071379L (no) Oksazolo-naftylsyrer som plaminogen aktivator inhibitor type-1 (PAI-1) modulatorer for behandling av trombose og kardiovaskulaere sykdommer.
NO20061291L (no) Ny formulering
WO2004052236A3 (fr) Methodes et compositions de traitement de l'otite moyenne
TW200745047A (en) Heterocyclic compounds
MXPA06014535A (es) Indoles utiles en el tratamiento de la inflamacion.
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
WO2003095475A8 (fr) Composes peptidiques et leur utilisation comme substrats de proteases
AU2003301903A1 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application